Identification of Novel Fusions and Pharmacogenomic Targets in Cancer

1 May 2017

This webinar describes the optimization and validation of two commercially available clinical research next-generation sequencing (NGS) assays. The first assay is aimed at identifying fusion transcripts and can identify novel fusion partners. The second assay is used to detect pharmacogenomic targets in cancers that have not responded to current standard treatment. This webinar focuses on sarcoma samples, but the approaches used are applicable to different cancer types including other solid tumors and hematological malignancies. View related videos Next generation sequencing-based analyses of hematological malignancies http://youtu.be/Lb0zyXEpquc View related information TruSight RNA Fusion Panel http://www.illumina.com/RNAFusion Cancer Cytogenetics Solutions https://www.illumina.com/areas-of-interest/cancer/clinical-cancer-research/cancer-cytogenetics.html Introduction to Cytogenomics https://www.illumina.com/techniques/popular-applications/cytogenomics.html Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc For Research Use Only. Not for use in diagnostic procedures.

Share this article on